Shots:

• Twist to receive an up front for each program and $710M in clinical- regulatory- and commercial milestones for the multiple target discovery programs
• Boehringer Ingelheim obtains global exclusive rights to develop and commercialize any therapeutic Ab discovered under the collaboration
• The collaboration will utilize Twist’s Ab libraries that derived from human sequences to discover therapeutic Abs against multiple targets

| Ref: | Image: PharmaLive